Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9961149 | 0.86 | CA12 (0.32) | CA12CA14 | |
| SCHEMBL9961099 | 0.81 | HDAC3 (0.35) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19015739 | 0.81 | HDAC3 (0.35) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7890398 | 0.79 | CYP2D6 (0.45) | CYP2D6CA12CA14CA2 | |
| SCHEMBL9961215 | 0.77 | HDAC3 (0.35) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7357649 | 0.74 | HDAC3 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7357655 | 0.74 | HDAC3 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7357659 | 0.74 | HDAC3 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7966285 | 0.73 | CTSK (0.42) | CYP2D6CA12CA14CA2 | |
| SCHEMBL19015909 | 0.73 | CTSK (0.42) | CYP2D6CA12CA14CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288615-B1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-06-21 | — | — | EP | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | CASP3, CASP1, HTRA2 | CYP2D6 2204/4885HDAC3 175/4885HDAC1 260/4885 |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, HTRA2 | CYP2D6 2204/4885HDAC3 175/4885HDAC1 260/4885 |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | CYP2D6 1664/4885HDAC3 552/4885HDAC1 717/4885 |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | CYP2D6 1923/4885HDAC3 274/4885HDAC1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.